GlassScriptPhysician profile
Maria C Baxter
NPI 1770903601
$4,934.87
in general payments reported to CMS, 2019-2025
30 companies · $1,455 in 2025
The $1,455 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $1,130 · 2023: $934 · 2024: $1,251 · 2025: $1,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,640.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $793.06 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Amgen INC. | $381.85 | 2024-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $332.15 | 2021-2024 | Fasenra |
| Emd Serono, INC. | $254.51 | 2023-2024 | |
| Abbvie INC. | $223.25 | 2022 | |
| Alexion Pharmaceuticals, INC. | $220.65 | 2023 | Ultomiris |
| Phathom Pharmaceuticals, INC. | $219.12 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $213.50 | 2023-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $211.12 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $158.12 | 2022 | |
| Sumitomo Pharma America, INC. | $125.73 | 2024 | Gemtesa |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Novo Nordisk INC | $124.61 | 2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.84 | 2024 | Caplyta |
| Urovant Sciences INC | $120.00 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $119.86 | 2023 | |
| Sanofi Pasteur INC. | $107.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.10 | 2023 | |
| Sage Therapeutics, LLC | $99.17 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $96.66 | 2025 | |
| Hologic Sales and Service, LLC | $94.55 | 2025 | Aptima |
| Dexcom, INC. | $93.23 | 2024 | Dexcom G6 Transmitter |
| Biogen, INC. | $92.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $87.56 | 2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.90 | 2025 | Xifaxan |
| Insmed, INC. | $72.42 | 2025 | Arikayce |
| Merck Sharp & Dohme LLC | $71.68 | 2025 | Capvaxive |
| Smith+Nephew, INC. | $70.04 | 2022 | |
| Acadia Pharmaceuticals INC | $61.82 | 2021 | |
| Neurocrine Biosciences, INC. | $55.44 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.